Larimar Therapeutics (NASDAQ:LRMR – Get Free Report) released its quarterly earnings results on Monday. The company reported ($0.29) EPS for the quarter, beating the consensus estimate of ($0.35) by $0.06, FiscalAI reports.
Larimar Therapeutics Trading Down 0.7%
Shares of LRMR opened at $3.00 on Tuesday. The firm has a fifty day simple moving average of $2.92 and a 200 day simple moving average of $3.76. Larimar Therapeutics has a 12 month low of $1.91 and a 12 month high of $6.42. The stock has a market capitalization of $311.64 million, a price-to-earnings ratio of -1.54 and a beta of 0.73.
Wall Street Analysts Forecast Growth
LRMR has been the subject of several research analyst reports. Leerink Partners initiated coverage on shares of Larimar Therapeutics in a research report on Monday, September 14th. They issued an “outperform” rating and a $13.00 price objective for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Larimar Therapeutics in a research report on Thursday, October 15th. Wall Street Zen lowered Larimar Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Saturday. Finally, Wedbush set a $9.00 target price on shares of Larimar Therapeutics in a report on Monday. Two analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $10.00.
Check Out Our Latest Stock Analysis on LRMR
Insider Buying and Selling
In related news, CFO Michael Celano bought 18,460 shares of the company’s stock in a transaction that occurred on Wednesday, November 11th. The shares were acquired at an average price of $2.71 per share, for a total transaction of $50,026.60. Following the completion of the acquisition, the chief financial officer owned 234,245 shares of the company’s stock, valued at approximately $634,803.95. The trade was a 8.55% increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Carole Ben-Maimon purchased 18,050 shares of Larimar Therapeutics stock in a transaction that occurred on Wednesday, November 11th. The shares were bought at an average cost of $2.77 per share, with a total value of $49,998.50. Following the completion of the transaction, the chief executive officer directly owned 386,326 shares of the company’s stock, valued at approximately $1,070,123.02. The trade was a 4.90% increase in their position. The SEC filing for this purchase provides additional information. Insiders acquired a total of 140,810 shares of company stock worth $381,955 in the last three months. Insiders own 4.00% of the company’s stock.
Larimar Therapeutics Company Profile
Larimar Therapeutics, Inc. is a clinical-stage biotechnology company headquartered in Bala Cynwyd, Pennsylvania, focused on developing treatments for rare diseases. Its lead drug candidate is nomlabofusp, formerly known as CTI-1601, an engineered fusion protein designed to deliver frataxin to mitochondria. Nomlabofusp is being developed to treat Friedreich’s ataxia, a rare, inherited neurodegenerative disorder associated with insufficient frataxin. Larimar’s approach uses a cell-penetrating peptide to transport frataxin into cells and mitochondria, with the goal of addressing an underlying cause of the disease rather than only treating its symptoms.
Read More
- Five stocks we like better than Larimar Therapeutics
- Microsoft’s Outage Barely Moved Its Stock, But a Bigger Risk May Be Building
- MongoDB’s Biggest Advantage May Be GitLab’s Biggest Weakness
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
Receive News & Ratings for Larimar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Larimar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
